Deutsche Bank AG Makes New Investment in Elanco Animal Health Incorporated $ELAN

Key Points

• Deutsche Bank acquired 120,333 Elanco shares worth approximately $2.96 million during the second quarter. Institutional investors collectively own 97.48% of ELAN, with several major funds increasing their positions.
• Analysts remain generally positive, with Elanco receiving a “Moderate Buy” consensus rating and an average price target of $29.09. Recent target increases came from TD Cowen, UBS, and JPMorgan, although Weiss Ratings maintained a sell rating.
• Elanco exceeded quarterly expectations, reporting adjusted EPS of $0.34 versus a $0.27 estimate and revenue of $1.37 billion, up 10.2% year over year. Company insiders also purchased 63,198 shares worth approximately $1.47 million in the latest quarter.

Deutsche Bank AG acquired a new position in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 120,333 shares of the company's stock, valued at approximately $2,961,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of ELAN. T. Rowe Price Investment Management Inc. raised its stake in Elanco Animal Health by 11.8% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 35,227,418 shares of the company's stock valued at $797,197,000 after purchasing an additional 3,717,404 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Elanco Animal Health by 1.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 25,082,545 shares of the company's stock worth $567,622,000 after buying an additional 373,869 shares during the last quarter. UBS Group AG raised its position in shares of Elanco Animal Health by 56.7% during the 3rd quarter. UBS Group AG now owns 16,468,148 shares of the company's stock valued at $331,669,000 after buying an additional 5,961,457 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Elanco Animal Health by 7.3% during the 4th quarter. Geode Capital Management LLC now owns 9,425,533 shares of the company's stock valued at $213,343,000 after buying an additional 640,098 shares in the last quarter. Finally, Fuller & Thaler Asset Management Inc. lifted its holdings in shares of Elanco Animal Health by 16.1% in the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 5,771,622 shares of the company's stock valued at $130,612,000 after acquiring an additional 799,745 shares during the last quarter. 97.48% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. TD Cowen raised their price objective on Elanco Animal Health from $31.00 to $32.00 and gave the company a "buy" rating in a research note on Thursday, June 18th. UBS Group boosted their target price on Elanco Animal Health from $31.00 to $33.00 and gave the company a "buy" rating in a research report on Thursday, August 6th. Morgan Stanley increased their price target on Elanco Animal Health from $23.00 to $26.00 and gave the company an "equal weight" rating in a report on Wednesday, July 22nd. JPMorgan Chase & Co. raised their price target on Elanco Animal Health from $28.00 to $30.00 and gave the stock an "overweight" rating in a research report on Thursday, May 7th. Finally, Weiss Ratings lowered shares of Elanco Animal Health from a "sell (d+)" rating to a "sell (d)" rating in a research note on Thursday, August 20th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, Elanco Animal Health presently has an average rating of "Moderate Buy" and an average price target of $29.09.

Elanco Animal Health Price Performance

Shares of ELAN opened at $25.09 on Thursday. The firm has a fifty day moving average price of $24.61 and a 200-day moving average price of $24.01. The company has a current ratio of 2.05, a quick ratio of 1.10 and a debt-to-equity ratio of 0.58. The firm has a market capitalization of $12.54 billion, a P/E ratio of -61.20, a P/E/G ratio of 1.50 and a beta of 1.67. Elanco Animal Health Incorporated has a 12-month low of $17.11 and a 12-month high of $27.98.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $0.34 EPS for the quarter, topping the consensus estimate of $0.27 by $0.07. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The company had revenue of $1.37 billion for the quarter, compared to the consensus estimate of $1.31 billion. During the same quarter last year, the firm posted $0.26 EPS. The firm's revenue was up 10.2% compared to the same quarter last year. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. Equities research analysts expect that Elanco Animal Health Incorporated will post 1.12 earnings per share for the current year.

Insider Buying and Selling at Elanco Animal Health

In related news, insider Shiv O'neill purchased 3,998 shares of the firm's stock in a transaction dated Tuesday, August 18th. The stock was purchased at an average price of $23.58 per share, with a total value of $94,272.84. Following the completion of the purchase, the insider owned 87,832 shares of the company's stock, valued at approximately $2,071,078.56. The trade was a 4.77% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Robert M. Vanhimbergen acquired 4,200 shares of the company's stock in a transaction that occurred on Friday, August 7th. The stock was purchased at an average cost of $23.08 per share, for a total transaction of $96,936.00. Following the purchase, the chief financial officer owned 137,516 shares of the company's stock, valued at $3,173,869.28. This represents a 3.15% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders bought 63,198 shares of company stock valued at $1,473,109. 1.14% of the stock is owned by corporate insiders.

Elanco Animal Health Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco's portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source